Price to sales forward of Nu Skin Enterprises, Inc. Class A – LS:903911
This article provides the "Price to sales forward" metric for Nu Skin Enterprises, Inc. Class A (LS:903911) on TradingView. It includes basic company information and navigational elements to other financial data, news, and community features on the platform. The core content is the specific financial metric displayed, indicating that trading is currently closed.
Price to book forward of Nu Skin Enterprises, Inc. Class A – LS:903911
This article provides the "Price to book forward" for Nu Skin Enterprises, Inc. Class A (LS:903911). It is presented within the context of financial data available on TradingView for the company. The content appears to be a stub or a data point rather than a full analytical article.
Nu Skin Enterprises, Inc. Class A Actuals & Estimates (NYSE:NUS)
This article provides an overview of Nu Skin Enterprises, Inc. (NYSE:NUS) stock performance, financial actuals and estimates. It covers the current stock price, historical highs and lows, volatility, market capitalization, earnings, revenue, dividends, and employee count. The article also touches upon technical analysis ratings for the stock.
Nu Skin (NUS) director Edwina Woodbury adds shares through dividend reinvestment
Nu Skin Enterprises (NUS) director Edwina D. Woodbury acquired 19 shares of Class A Common Stock at $5.43 per share through a dividend reinvestment under the Company's Deferred Compensation Plan. Following this transaction, her direct holdings increased to 62,452 shares. This Form 4 filing indicates a compensation-related acquisition rather than an open-market purchase.
Nu Skin Enterprises director Edwina Woodbury sells $41,057 in stock By Investing.com
Nu Skin Enterprises director Edwina Woodbury executed a sale of 7,203 company shares totaling $41,057 on June 1, 2026, as part of a Rule 10b5-1 trading plan. On the same day, Woodbury acquired 26,643 shares at $0.00 each. These transactions occurred while Nu Skin's stock (NASDAQ:NUS) trades near its 52-week low and is considered undervalued by InvestingPro analysis, following a challenging quarter with earnings and revenue falling short of analyst expectations.
Nu Skin Enterprises director Edwina Woodbury sells $41,057 in stock
Nu Skin Enterprises director Edwina Woodbury sold 7,203 shares of company stock for $41,057 on June 1, 2026, as part of a pre-arranged trading plan. On the same day, she acquired 26,643 shares at $0.00 each, increasing her direct holdings to 62,433 shares. This transaction occurred amidst the company's shares trading near their 52-week low and after a first-quarter earnings miss.
Nu Skin Enterprises director Edwina Woodbury sells $41,057 in stock
Nu Skin Enterprises director Edwina Woodbury sold 7,203 shares of the company's Class A Common Stock for $41,057 on June 1, 2026, pursuant to a Rule 10b5-1 trading plan. On the same day, Woodbury acquired 26,643 shares at $0.00 per share, bringing her direct holdings to 62,433 shares. This transaction occurred as Nu Skin shares trade near their 52-week low, following a first-quarter 2026 earnings report that missed analyst expectations for both EPS and revenue.
Nu Skin director James Winett sells $40,480 in shares
Nu Skin director James M. Winett sold 7,203 shares of Class A Common Stock for $40,480 at $5.62 per share on June 2, 2026, following an acquisition of 26,643 shares at $0.00 each on June 1, 2026. This transaction was part of a Rule 10b5-1(c) trading plan adopted in November 2025, occurring as the stock trades near its 52-week low. The sale follows a disappointing first-quarter 2026 earnings report where Nu Skin missed analyst expectations for both EPS and revenue.
Nu Skin director James Winett sells $40,480 in shares
Nu Skin director James Winett recently sold 7,203 shares of Class A Common Stock for $40,480, following an acquisition of 26,643 shares at $0.00. The sale occurred pursuant to a 10b5-1 trading plan and comes as the stock trades near its 52-week low. The company also reported first-quarter 2026 earnings that missed analyst expectations for both EPS and revenue.
Nu Skin Enterprises director Edwina Woodbury sells $41,057 in stock
Nu Skin Enterprises director Edwina Woodbury sold 7,203 shares of Class A Common Stock for $41,057 on June 1, 2026, as part of a Rule 10b5-1 trading plan. On the same day, she acquired 26,643 shares at $0.00 each, increasing her direct holdings to 62,433 shares. This transaction occurred as Nu Skin shares trade near their 52-week low, and the company recently reported first-quarter 2026 earnings that missed analyst expectations.
Nu Skin (NUS) director sells 7,203 shares and gets 26,643-share grant
Nu Skin Enterprises, Inc. director Edwina D. Woodbury reported both a sale and a grant of Class A Common Stock on June 1, 2026. She sold 7,203 shares at $5.70 per share under a pre-arranged trading plan, and simultaneously acquired 26,643 shares through a grant. Following these transactions, her direct holdings increased to 69,636 shares.
Nu Skin (NUS) director sells 7,203 shares under 10b5-1 trading plan
Nu Skin Enterprises director James M. Winett recently reported an acquisition of 26,643 Class A Common Stock shares as a grant on June 1, 2026, and a subsequent sale of 7,203 shares at $5.62 per share on June 2, 2026, under a Rule 10b5-1 trading plan. Following these transactions, Winett directly holds 37,448 shares, indicating a net increase in his holdings despite the sale. The sale was executed under a pre-arranged trading plan adopted in November 2025.
Nu Skin (NUS) director awarded 26,643 Class A shares, now holds 116,827
Nu Skin Enterprises, Inc. director Thomas R. Pisano was awarded 26,643 shares of Class A Common Stock as equity compensation on June 1, 2026, at no purchase price. This transaction increased his direct holdings to 116,827 shares. The filing indicates this was a compensation-related grant rather than an open-market purchase, reinforcing his equity stake in the company.
Nu Skin (NUS) director receives 26,643-share equity grant
Nu Skin Enterprises, Inc. director Daniel W. Campbell was granted 26,643 shares of Class A Common Stock at no cost, increasing his direct holdings to 65,859 shares. The filing also detailed his indirect ownership, which includes 10,010 shares through a limited liability company and 53,375 shares via an irrevocable family trust. This transaction is a compensation-related equity award, not an open-market purchase or sale.
Director Emma S. Battle receives 26,643 NU SKIN (NUS) shares in equity grant
NU SKIN (NUS) director Emma S. Battle received an equity grant of 26,643 Class A Common Stock shares at $0.0000 per share, increasing her direct holdings to 57,648 shares. This transaction, a compensation-related award rather than an open-market purchase, is classified as a non-derivative equity grant. The grant was reported on an SEC Form 4 filing dated June 3, 2026, with an effective transaction date of June 1, 2026.
NU SKIN (NUS) director Nathanson receives 26,643-share Class A stock grant
NU SKIN ENTERPRISES, INC. director Laura Nathanson was granted 26,643 shares of Class A Common Stock on June 1, 2026, as part of her compensation, with no purchase price. This transaction increased her direct holdings to 57,116 shares. The filing indicates a routine equity grant aligning her interests with shareholders, with no sales or other transactions reported.
Director Mark A. Zorko receives 26,643-share equity grant at NU SKIN (NUS)
NU SKIN (NUS) director Mark A. Zorko was granted 26,643 shares of Class A Common Stock on June 1, 2026, at no purchase price, as per a Form 4 filing. This compensation-related equity award increased his direct holdings to 60,586 shares. The transaction code "A" signifies a grant or acquisition, not an open-market purchase.
Nu Skin director James Winett sells $40,480 in shares By Investing.com
Nu Skin Enterprises director James M Winett sold 7,203 shares of Class A Common Stock for $40,480 on June 2, 2026, at a price of $5.62 per share. This transaction followed an acquisition of 26,643 shares at $0.00 each on June 1, 2026, leaving him with 37,448 shares. The sale occurred as NU SKIN stock is near its 52-week low, and prior to this, the company reported first-quarter 2026 earnings and revenue below analyst expectations.
NU SKIN ENTERPRISES, INC. SEC Filing
This article details a recent Form 144 SEC filing by NU SKIN ENTERPRISES, INC. (NUS) concerning a proposed sale of securities. The filing indicates a sale of 7,203 Class A shares, acquired through restricted stock vesting, with an aggregate market value of $40,480.86, to be executed on June 2, 2026, via Fidelity Brokerage Services LLC. The document also includes standard representations regarding material adverse information and details of the acquisition of the securities.
[144] NU SKIN ENTERPRISES, INC. SEC Filing
This article reports on a Form 144 SEC filing by NU SKIN ENTERPRISES, INC. (NUS). The filing indicates a proposed sale of Class A securities totaling 7203 units with an aggregate market value of $41,057.10, acquired through restricted stock vesting. The proposed sale date is June 1, 2026, through Fidelity Brokerage Services LLC on the NYSE.
Nu Skin (NUS) investors approve incentive plan, pay and full board slate
Nu Skin Enterprises, Inc. stockholders approved the Amended and Restated 2024 Omnibus Incentive Plan, advisory approval of executive compensation, and the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm at their 2026 Annual Meeting. All nine director nominees were also elected. The approved incentive plan includes an increase in share authorization and an extended termination date to May 28, 2036.
Nu Skin Enterprises' (NYSE:NUS) Profits May Not Reveal Underlying Issues
Nu Skin Enterprises' recent solid earnings report might be misleading due to a significant boost from unusual items. Investors are advised to look beyond statutory profits, as these unusual gains are unlikely to recur, suggesting the company's underlying profitability may be lower. The article suggests considering other factors like return on equity and insider ownership for a comprehensive understanding.
Nu Skin Reaches 900 Million Meals Purchased and Donated in its Global Fight for Child Nutrition
Nu Skin Enterprises, Inc. announced a significant milestone, having provided 900 million meals to children globally through its "Nourish the Children" initiative since 2002. This program, supported by sales leaders, customers, and employees, distributes nutrient-dense VitaMeal to malnourished children in over 65 countries via third-party charity partners. The company continues to feed approximately 75,000 children daily, aiming for a total of 1 billion meals.
Nu Skin Enterprises director Laura Nathanson sells $18,009 in shares By Investing.com
Nu Skin Enterprises director Laura Nathanson sold 2,676 shares of Class A Common Stock for $18,009 on May 11, 2026. This transaction occurred as NUS stock trades near its 52-week low, despite InvestingPro analysis suggesting it is significantly undervalued. The sale follows Nu Skin's first-quarter 2026 earnings, which missed analyst expectations for EPS and revenue.
Nu Skin Enterprises director Laura Nathanson sells $18,009 in shares
Nu Skin Enterprises director Laura Nathanson sold 2,676 shares of the company's Class A Common Stock for $18,009 on May 11, 2026. This insider sale occurred as NUS stock trades near its 52-week low, despite InvestingPro analysis suggesting the stock is significantly undervalued. The company recently reported Q1 2026 earnings and revenue that missed analyst expectations, leading to a decline in stock price.
Charles Schwab holds 2.14M Nu Skin shares (NUS) — 4.45% stake
Charles Schwab Investment Management Inc. has filed an amended Schedule 13G, disclosing a 4.45% ownership stake in Nu Skin Enterprises' Class A Common Stock, totaling 2,143,294 shares. The filing indicates Charles Schwab holds sole voting and dispositive power over these shares. This passive investment is below the 5% threshold, signifying no intent to influence corporate governance or control.
Nu Skin Enterprises director Laura Nathanson sells $18,009 in shares By Investing.com
Nu Skin Enterprises director Laura Nathanson sold 2,676 shares of the company's Class A Common Stock for $18,009. This transaction occurred on May 11, 2026, with the stock trading near its 52-week low. The sale follows disappointing first-quarter earnings that fell short of analyst expectations, leading to a decline in Nu Skin's stock price.
Nu Skin Enterprises director Laura Nathanson sells $18,009 in shares
Nu Skin Enterprises director Laura Nathanson sold 2,676 shares of Class A Common Stock for $18,009 on May 11, 2026. This transaction follows a period where NUS stock trades near its 52-week low and the company reported Q1 2026 earnings and revenue below analyst expectations. Nathanson now holds 30,473 shares directly.
Nu Skin Enterprises director Laura Nathanson sells $18,009 in shares By Investing.com
Nu Skin Enterprises director Laura Nathanson sold 2,676 shares of Class A Common Stock for a total of $18,009. The sale occurred on May 11, 2026 and comes as the stock trades near its 52-week low. Despite a recent decline in stock price and first-quarter earnings missing analyst expectations, InvestingPro analysis indicates the stock may be significantly undervalued.
Nu Skin Enterprises director Laura Nathanson sells $18,009 in shares
Laura Nathanson, a director at Nu Skin Enterprises (NYSE:NUS), sold 2,676 shares of Class A Common Stock for a total of $18,009 on May 11, 2026. This insider sale occurred as NUS stock approached its 52-week low. The company recently reported first-quarter 2026 earnings below analyst expectations, with adjusted EPS of $0.14 and revenue of $320.6 million.
[Form 4] NU SKIN ENTERPRISES, INC. Insider Trading Activity
Nu Skin Enterprises director Laura Nathanson sold 2,676 shares of Class A Common Stock at $6.73 per share in an open-market transaction. Following the sale, she directly holds 30,473 shares, indicating the transaction was a relatively small portion of her total holdings and is likely a routine liquidity event rather than a change in her investment thesis. The Form 4 filing confirmed this non-derivative transaction and provided details on her remaining direct beneficial ownership.
Nu Skin (NUS) Form 144: William Blair named for 49.5M Class A share listing
Nu Skin Enterprises filed a Form 144 notice revealing a proposed sale of 49,497,715 Class A common shares through William Blair and Company LLC on the NYSE, dated May 11, 2026. The filing also detailed prior compensatory dispositions of Class A shares on April 30, 2024, and May 29, 2025. This notice indicates potential trading activity for a significant number of Nu Skin's Class A shares.
Nu Skin Enterprises (NUS) One Off Gain Raises Questions For Earnings Decline Narratives
Nu Skin Enterprises (NUS) reported FY 2025 results with a significant one-off gain of US$151.0 million, which boosted its reported profitability to US$3.25 EPS for the trailing twelve months. Despite this gain and a current P/E of 2.2x, the company faces skepticism due to a 38.5% historical decline in earnings and a forecasted 51.6% yearly decline over the next three years, along with modest 1.5% revenue growth outlook. The article questions the durability of current margins and highlights the tension between the low P/E valuation and the weak earnings trajectory.
Nu Skin (NYSE: NUS) product chief resigns but remains strategic advisor
Nu Skin Enterprises (NYSE: NUS) announced that Steven K. Hatchett has resigned from his position as Executive Vice President and Chief Product Officer, effective May 8, 2026, due to family health circumstances. He will continue to serve the company as a strategic product advisor with an annual salary of $147,478. The company expressed appreciation for his contributions as Chief Product Officer.
Nu Skin (NYSE: NUS) Q1 2026 sales drop 12% as earnings shrink
Nu Skin Enterprises reported a significant decline in its Q1 2026 financial performance, with revenue falling 12% to $320.6 million and net income plummeting to $1.8 million from $107.5 million in the prior-year quarter. The drop in earnings is largely attributed to the absence of a large gain from the sale of the Mavely business seen in Q1 2025, combined with $5.9 million in charges related to winding down the BeautyBio business and ongoing macroeconomic pressures affecting consumer spending and customer acquisition. The company is focusing on business model optimization, the rollout of its Prysm iO wellness platform, and expansion into India to counter these challenges, while maintaining a manageable debt level and continuing capital returns through dividends and share repurchases.
Working capital per share of Nu Skin Enterprises, Inc. Class A – TRADEGATE:NUS
The article provides information regarding the working capital per share for Nu Skin Enterprises, Inc. Class A (TRADEGATE:NUS) on TradingView. It indicates that the market is closed and offers navigation to financial data, news, and community sections for the company.
NUS SEC Filings - Nu Skin Enter 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Nu Skin Enterprises (NUS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider trading forms. It features details about the company's financial performance, business model, and recent insider transactions. The platform also offers AI-powered summaries of these filings to help investors quickly grasp key insights.
Nu Skin Enterprises to Announce First Quarter 2026 Financial Results
Nu Skin Enterprises (NYSE: NUS) announced it will release its first-quarter 2026 financial results after market close on Thursday, May 7, 2026. Management will host a conference call at 5 p.m. ET on the same day to discuss the results and upcoming business initiatives. A webcast of the conference call and financial information will be available on the company's investor relations website.
Nu Skin (NUS) outlines 2026 votes, 2025 results and CEO pay in proxy
Nu Skin Enterprises (NUS) released its definitive proxy statement outlining proposals for its May 28, 2026 annual meeting, including the election of nine directors, an advisory vote on executive compensation, approval of an amended incentive plan, and auditor ratification. The company detailed its 2025 financial performance, reporting $1.49 billion in revenue and showcasing its performance-based executive pay structure, which resulted in reduced cash incentives due to financial metrics falling below target levels. CEO Ryan Napierski's 2025 compensation totaled $5.97 million, predominantly equity-based, and the company emphasized strong corporate governance practices and sustainability initiatives.
Nu Skin Launches Prysm iO™: A Revolutionary AI-Powered Platform for Personalized Nutritional Wellness
Nu Skin Enterprises Inc. has launched Prysm iO™, an AI-powered platform designed to provide personalized nutritional wellness insights to consumers in the U.S., with global expansion planned. This intelligent device noninvasively scans fingertip carotenoid levels in 15 seconds, offering a "Nutrition Health Score" based on over two decades of research and a database of 20 million antioxidant scans. Prysm iO aims to empower users to make informed wellness decisions and track the effectiveness of their nutrition and supplement routines, integrating with Nu Skin's existing wellness ecosystem.
Nu Skin (NUS) CFO Chelsea Lantz discloses 42,100-share Class A stake
Nu Skin Enterprises' Chief Financial Officer, Chelsea K. Lantz, has filed an initial Form 3, disclosing her beneficial ownership of 42,100 shares of Class A Common Stock. This filing establishes her equity position as an executive officer. The Form 3 is an initial statement and does not represent a buy or sell transaction.
Nu Skin (NYSE: NUS) adds $175M term loan and $75M revolver
Nu Skin Enterprises (NYSE: NUS) has secured a new Second Amended and Restated Credit Agreement on March 27, 2026, establishing a $175 million term loan and a $75 million revolving credit facility, both with five-year terms. The term loan was fully drawn at closing to refinance its prior bank debt, effectively reshaping its financing structure without adding new net debt. The new agreement includes financial covenants such as a maximum consolidated leverage ratio of 2.25 to 1.00 and a minimum interest coverage ratio of 3.00 to 1.00.
Vanguard disaggregates holdings; reports 0 shares of Nu Skin (NYSE: NUS)
The Vanguard Group has reported holding 0 shares (0%) of Nu Skin Enterprises Inc. (NYSE: NUS) common stock following an internal realignment on January 12, 2026. This change is due to certain Vanguard subsidiaries now reporting their beneficial ownership separately, as permitted by SEC Release No. 34-39538. The Schedule 13G/A filing, signed by Ashley Grim, Head of Global Fund Administration, indicates that Vanguard is no longer deemed to beneficially own securities held by these disaggregated subsidiaries.
CFO change at Nu Skin (NYSE: NUS) as Chelsea Lantz steps in
Nu Skin Enterprises announced that its EVP and CFO, James D. Thomas, resigned on March 17, 2026. The company's board has appointed Chelsea K. Lantz, Vice President and Corporate Controller, as interim CFO, effective March 18, 2026, while a search for a permanent replacement is underway. Lantz, who has been with Nu Skin since 2011, will receive an annual salary of $300,000, a 35% target incentive bonus, and a $25,000 quarterly stipend in her interim role.
NU SKIN ENTERPRISES, INC.
This article announces that Nu Skin Enterprises Inc. filed a Form 8K for March 20. The filing was published on March 20, 2026, at 04:20 PM. The text also displays current trading data for NUS stock and various market indices.
Nu Skin Enterprises Appoints Chelsea Lantz as Interim Chief Financial Officer
Nu Skin Enterprises has appointed Chelsea Lantz as its interim Chief Financial Officer, effective immediately. This appointment follows James Thomas's departure to pursue another opportunity. Lantz, who previously served as corporate controller and led cost-improvement efforts, will help guide the company's financial transformation while a search for a permanent CFO is underway.
Portolan Capital Management LLC Purchases Shares of 596,724 Nu Skin Enterprises, Inc. $NUS
Portolan Capital Management LLC has acquired 596,724 shares of Nu Skin Enterprises (NYSE:NUS) with a value of approximately $7.27 million, representing a 1.21% ownership stake. This move is part of broader institutional interest in Nu Skin, with other firms like Prudential and American Century also increasing their holdings. Despite these investments, Nu Skin recently missed EPS and revenue estimates and has received mixed to negative analyst ratings.
NU SKIN (NUS) CEO Ryan Napierski receives 282,353-share equity grant
NU SKIN ENTERPRISES, INC. President and CEO Ryan S. Napierski was granted 282,353 shares of Class A Common Stock on March 6, 2026, increasing his direct holdings to 1,001,905 shares. The shares were acquired at $0.00 per share as an award, indicated by a transaction code "A" on the SEC Form 4 filing. This filing does not report any sales or disposals by the CEO.
Nu Skin (NUS) Chief Product Officer granted 77,941 Class A shares in Form 4
Nu Skin Enterprises' Chief Product Officer, Steven Keith Hatchett, was granted 77,941 shares of Class A common stock on March 6, 2026, as reported in a Form 4 SEC filing. This non-cash award at $0.00 per share increased Hatchett's direct ownership to 260,818 shares. The transaction code "A" confirms it was a grant or award acquisition, not a stock purchase.
Nu Skin (NUS) EVP Justin Keisel receives 47,059-share equity grant
Justin S. Keisel, EVP and President of Global Sales at Nu Skin Enterprises, Inc. (NUS), received an equity grant of 47,059 shares of Class A Common Stock. This grant was awarded at $0.00 per share, indicating it was an equity grant rather than a market purchase. Following this transaction, Keisel directly holds 160,170 shares of Nu Skin Class A Common Stock.
